Les facteurs prédictifs de rechute de la maladie de Basedow traitée par ATS : à propos de 72 cas

Bouziane, T.; Larwanou, Maazou Mahamane; Ouahabi, H. El

doi:10.1016/j.ando.2017.07.370

Search citation statements

Order By: Relevance

Paper Sections

Select...

Age1

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The female predominance in our study at 80% was also reported by: Ben Sellem D et al, Tunis [15] (80%), Alaya W et al [8], Mahdia [9] (80%), DohoHiro BG et al in Bamako, [12] (83%), Mbodj M et al, Rabat [10] (79%).…”

Section: Agesupporting

confidence: 85%

See 1 more Smart Citation

Iodine 131 Treatment in Graves’ Disease in a West African Country: Preliminary Study about 25 Cases in Senegal

Bathily,

Badiane,

Djigo

et al. 2024

OJBIPHY

View full text Add to dashboard Cite

57Open Journal of Biophysics than 18 months in 92%. The empirically used iodine-131 activity averaged 15.35 mCi. Oral corticosteroid therapy was prescribed in 7 patients for the prevention of malignant orbitopathy. No early side effects were noted. The remission rate at 3 months was 52% and at 6 months was 88% to 92%. Conclusion: The effectiveness of radioactive iodine, in particular ablative doses in the treatment of hyperthyroidism, is no longer to be demonstrated. Taking into account our socioeconomic context, iratherapy should be a treatment of choice for hyperthyroidism with a good quality/price ratio and excellent tolerance.

show abstract

Section: Agesupporting

confidence: 85%

“…First-line treatment for Graves' disease (BD) does not follow a particular consensus [8]. Three therapeutic modalities dominate treatment: -Medical treatment with synthetic antithyroid drugs (SAT) that effectively restore euthyroidism [9]. Medical treatment with SAT is usually offered for the first episode of autoimmune hyperthyroidism.…”

Section: Introductionmentioning

confidence: 99%